MSMB

Overview

MSMB (Microseminoprotein-beta) is a secreted protein with proposed tumor-suppressive and immune-modulatory roles. In HER2+ metastatic esophagogastric cancer, MSMB expression has been linked to trastuzumab resistance, potentially via hypoxia-driven MAPK pathway activation.

Alterations observed in the corpus

  • MSMB expression associated with trastuzumab + chemotherapy resistance in HER2+ esophagogastric cancer (EGC) by single-cell RNA-seq analysis; linked to hypoxia-driven MAPK pathway activation; identified as a candidate future therapeutic target PMID:37406106.

Cancer types (linked)

  • Esophagogastric cancer (HER2+) — MSMB-expressing subpopulations associated with trastuzumab resistance; identified via scRNA-seq from escape lesions PMID:37406106.

Co-occurrence and mutual exclusivity

  • Co-expressed with MT1H, MT1E, and MT2A (metallothioneins) as part of a resistance transcriptional program in HER2+ EGC escape lesions PMID:37406106.

Therapeutic relevance

  • MSMB-expressing resistance program identified as a candidate therapeutic target in HER2+ EGC; requires orthogonal preclinical validation PMID:37406106.

Open questions

  • The scRNA-seq resistance program (MT1H, MT1E, MT2A, MSMB) was identified from a small sample; functional validation of the MAPK/hypoxia axis is needed.

Sources

This page was processed by crosslinker on 2026-05-04.